Immunoglobulin therapy: Replacement and immunomodulation

Clinical Immunology: Principles and Practice: Fourth Edition

Volumn , Issue , 2013, Pages 1041-1053

  Ballow, Mark C ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875712003     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7234-3691-1.00098-2     Document Type: Chapter

References (93)

1. Orange J.S., Hossny E.M., Weiler C.R., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006, 117:S525-S553.
2. Quartier P., Debre M., DeBlie J., et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. J Pediatrics 1999, 134:589-596.
3. Busse P.J., Razvi S., Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002, 109:1001-1004.
4. Stiehm E.R., Orange J.S., Ballow M., Lehman H. Therapeutic use of immunoglobulins. Adv Pediatr 2010, 57:185-218.
5. Bonagura V.R., Marchlewski R., Cox A., Rosenthal D.W. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008, 122:210-212.
6. Lucas M., Lee M., Lortan J., et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobuin therapy over 22 years. J Allergy Clin Immunol 2010, 125:1354-1360.
7. Fasth A., Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008, 28:370-378.
8. Gardulf A., Nicolay U., Math D., et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004, 114:936-942.
9. Nicolay U., Kiessling P., Berger M., et al. Health-related quality of life and treatment satisfaction in North American patients with primary immune deficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006, 26:65-72.
10. Misbah S., Sturzenegger M.H., Borte M.N., et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009, 158(Suppl. 1):51-59.
11. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunology 2004, 112:1-7.
12. Bonilla F.A. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008, 28(4):803-819.
13. Brannagan T.H., Nagle K.J., Lange D.J., Rowland L.P. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996, 47:674-677.
14. Dalakas M.C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994, 44(2):223-226.
15. Reinhart W.H., Berchtold P.E. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992, 339:662-664.
16. Burks A., Sampson H., Buckley R. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986, 314:560.
17. Thampakkul S., Ballow M. Replacement intravenous immune serum globulin therapy in patients with antibody immune deficiency. Allergy Immunol Clin North Am 2001, 21:165-184.
18. Qin Y.H., Zhou T.B., Su L.N., et al. The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials. Blood Coagul Fibrinolysis 2010, 21:713-721.
19. Tarantino M.D., Madden R.M., Fennewald D.L., et al. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin. J Pediatr 1999, 134(1):21-26.
20. o(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005, 106:1532-1537.
21. Yu Z., Lennon V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999, 340(3):227-228.
22. Hansen R.J., Balthasar J.P. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002, 100:2087-2093.
23. Hansen R.J., Balthasar J.P. PK/PD modeling of the effects of intravenous immunoglobulin on the disposition of anti-platelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 2003, 92:1206-1215.
24. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
25. Kaneko Y., Nimmerjahn F., Ravetch J. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673.
26. Anthony R., Nimmerjahn F., Ashline D., et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376.
27. Anthony R.M., Wermeling F., Karlsson M.C., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008, 105(50):19571-19578.
28. Proulx D., Aubin E., Lemieux R., Bazin R. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin Immunol 2010, 135:422-429.
29. Newburger J.W., Takahashi M., Beiser A.S., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633-1639.
30. Durongpisitkul K., Gururaj V.J., Park J.M., Martin C.F. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995, 96(6):1057-1061.
31. Son M.B., Gauvreau K., Burns J.C., et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki Disease: a retrospective study. J Pediatr 2011, 158:644-649.
32. Tsai M.-H., Huang Y.-C., Yen M.-H., et al. Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin. J Pediatr 2006, 148:38-43.
33. Leung D.Y.M. Immunologic aspects of Kawasaki syndrome. J Rheumatol 1990, (Suppl. 24):15-18.
34. Leung D.Y. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin Exp Immunol 1996, 104(Suppl. 1):49-54.
35. Vassilev T.L., Kazatchkine M.D., Van Huyen J.P.D., et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 2004, 93(11):3624-3631.
36. Gill V., Doig C., Knight D., et al. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005, 112:2031-2039.
37. Chang J., Shi P., Chiang E., Frenette P. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 2008, 111:915-923.
38. Furuno K., Yuge T., Kusuhara K., et al. CD25+CD4+ regulatory T cells in patients with Kawasaki disease. J Pediatrics 2004, 145:385-390.
39. Ephrem A., Chamat S., Miquel C., et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008, 111:715-722.
40. Kessel A., Ammuri H., Peri R., et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2010, 179:5571-5575.
41. Maddur M.S., Vani J., Hegde P., Lacroix-Desmazes S., et al. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 2011, 127:823-830.
42. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. J Am Med Assoc 2004, 2004:2367-2375.
43. Fergusson D., Hutton B., Sharma M., et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005, 45:1640-1657.
44. Elovaara I., Apostolski S., van Doorn P. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008, 15:893-908. Members of the Task Force.
45. Hughes R.A., Raphael J.C., Swan A.V., Doorn P.A. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2001, (2). [update of, CD002063; PMID: 11406030]. Cochrane Database Syst Rev 2004.
46. Yuki N., Ang C.W., Koga M., et al. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 2000, 47:314-321.
47. van Schaik I.N., Winer J.B., de Haan R., Vermeulen M. Intravenous immunoglobuline for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004, 2. CD001797.
48. Hughes R.A.C., Donofrio P., Bril V., et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008, 7:136-144.
49. Sater R.A., Rostami A. Treatment of Guillain-Barré Syndrome with intravenous immunoglobulin. Neurology 1998, 51(Suppl. 5):S9-S15.
50. Gajdos P., Tranchant C., Clair B., et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin - a randomized double-blind clinical trial. Arch Neurol 2005, 62:1689-1693.
51. Zinman L., Ng E., Bril V. IV immunoglobulin in patients with myasthenia gravis - a randomized controlled trial. Neurology 2007, 68:837-841.
52. Gajdos P., Chevret S., Clair B., et al. Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann N Y Acad Sci 1998, 841:720-776.
53. Dalakas M.C., Illa I., Dambrosia J.M., et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
54. Dalakas M.C. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998, 51(6 Suppl. 5):S2-S8.
55. Sorensen P.S., Fazekas F., Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002, 9:557-563.
56. Fazekas F., Strasser-Fuchs S., Hommes O.R. Intravenous immunoglobulin in MS: promise or failure?. J Neurol Sci 2007, 259:61-66.
57. Malik U., Oleksowicz L., Latov N., Cardo L.J. Intravenous γ-globulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol 1996, 39:136-139.
58. Liblau R., Gajdos P.H., Bustarret A., et al. Intravenous γ-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol 1991, 11:128-131.
59. Buchwald B., Ahangari R., Weishaupt A., Toyka K.V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol 2002, 51:673-680.
60. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol 1996, 104(Suppl. 1):21-25.
61. Dalakas M. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999, 22:1479-1497.
62. Arumugam T.V., Tang S.-C., Lathia J.D., et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A 2007, 104(35):14104-14109.
63. Giannini E.H., Lovell D.J., Silverman E.D. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1996, 23:919-924.
64. Kivity S., Katz U., Daniel N., et al. Evidence for the use of intravenous immunoglobulins-A review of the literature. Clinic Rev Allerg Immunol 2010, 38:201-269.
65. Mouthon L., Kaveri S.V., Spalter S.H., et al. Mechanisms of action of intravenous immune globuline in immune-mediated diseases. Clin Exp Immunol 1996, 104:3-9.
66. Gergely J., Sarmay G. Fc gamma RII-mediated regulation of human B cells. Scand J Immunol 1996, 44:1-10.
67. von Gunten S., Simon H.-U. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: Implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev 2008, 7:453-456.
68. St-Amour I., Laroche A., Bazin R., Lemieux R. Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. Clin Immunol 2009, 133:52-60.
69. Jordan S.C., Vo A.A., Tyan D., et al. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005, 9:408-415.
70. Vo A.A., Lukovsky M., Toyoda M., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008, 359(3):242-251.
71. Basta M., Kirshbom P., Frank M.M., Fries L. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin: attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989, 84:1974-1981.
72. 2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nature Med 2003, 9:431-438.
73. Shehata N., Palda V.A., Meyer R.M., et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev 2010, 24(Suppl. 1):S7-S27.
74. Kaul R., McGeer A., Norrby-Teglund A., et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study. Clin Infect Dis 1999, 28:800-807.
75. Abe R., Horiuchi A., Miyake M., Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994, 139:5-19.
76. Amemiya K., Dalakas M.C. Cytokine mRNA expression in the muscle of patients with inclusion body myositis (IBM) before and after treatment with steroids and intravenous immunoglobulin [Abstract]. Neurology 1997, 48:126.
77. Amemiya K., Semino-Mora C., Granger R.P., Dalakas M.C. Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000, 94:99-104.
78. Ankrust P., Muller F., Svenson M., et al. Administration of intravenous immunoglobulin (IVIg) in vivo downregulatory effects on the IL-1 system. Clin Exp Immunol 1999, 115:136-143.
79. Le Pottier L., Bendaoud B., Dueymes M., et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol 2007, 27(3):257-265.
80. Letko E., Papaliodis D.N., Papaliodis G.N., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005, 94:419-436.
81. Viard I., Wehrli P., Bullanim R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998, 282:490-493.
82. Faye O., Rouheau J.C. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg). Drugs 2005, 65:2085-2090.
83. Gurcan H.M., Jeph S., Ahmed A.R. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases-A review of the evidence for its efficacy and safety. Am J Clin Dermotol 2010, 11:315-326.
84. Jolles S. High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin Exp Immunol 2002, 129:385-389.
85. Mydlarski P.R., Ho V., Shear N.H. Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. J Cutaneous Med Surg 2006, 10(5):205-221.
86. Amagai M., Ikeda S., Shimizu H., et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009, 60:595-603.
87. Jolles S., Hughes J., Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998, 134:80-86.
88. Li N., Zhao M., Hilario-Vargas J., et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005, 115:3440-3450.
89. Mimouni D., Blank M., Payne A.S., et al. Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol 2010, 162:543-549.
90. Spahn J.D., Leung D.Y.M., Chan M.T.S., et al. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol 1999, 103:421-426.
91. Zhuang Q., Mazer B. Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin. J Allergy Clin Immun 2001, 108:229-234.
92. Wasserman R.L., Melamed I., Stein M., et al. Tolerability and efficacy of facilitated-subcutaneous infusion of immune globulin (human), 10% and recombinant human hyaluronidase (IGHy) in a subset of study patients with primary immunodeficiency disease (PIDD). J Allergy Clin Immunol 2012, 129(2). AB15. (Supplement.).
93. Anthony R.M., Kobayashi T., Wermeling F., Ravetch J.V. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011, 475:110-113.